NF-kB Inhibitors- Pipeline Insights, 2019

  • ID: 4600448
  • Drug Pipelines
  • Region: Global
  • DelveInsight
1 of 4

FEATURED COMPANIES

  • AnGes MG
  • Catabasis Pharmaceuticals
  • Constellation
  • Dendright
  • Incuron
  • MedDay Pharmaceutical
  • MORE
"NF-KB Inhibitors- Pipeline Insights, 2019" report outlays comprehensive insights of present scenario and growth prospects across NF-?B Inhibitors. A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type. This report provides detailed analysis of 12+ active products with more than 10 companies involved. Some of the key players include AMG0101 of AnGes MG and Bardoxolone methyl of Reata Pharmaceuticals, and BIIB098 of Alkermes/Biogen.

Products covered by Phase
  • Phase III, Phase II, Phase I
  • Pre-clinical
  • Inactive (Dormant and Discontinued)
Overview of pipeline development activities for NF-?B Inhibitors
Pipeline analysis of therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and pre-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.

Therapeutic segmentation of products for NF-?B Inhibitors
The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this mechanism.

Methodology

Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by the research team of industry experts.

Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report
  • Provides an overview of therapeutic pipeline activity for NF-?B Inhibitors across the complete product development cycle including all clinical and non-clinical stages
  • It comprises of detailed profiles of NF-?B Inhibitors therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, designations, technologies and chemical information
  • Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
  • Coverage of dormant and discontinued pipeline projects across NF-?B Inhibitors
Reasons to Buy
  • Establish a comprehensive understanding of the current pipeline scenario across NF-?B Inhibitors to formulate effective R&D strategies
  • Assess challenges and opportunities that influence NF-?B Inhibitors R&D
  • Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
  • Identify the relationship between the products and use it for target finding, drug repurposing, and precision medicine
  • Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for NF-?B Inhibitors to enhance and expand business potential and scope
  • Our extensive domain knowledge on therapy areas support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive and discontinued drugs
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AnGes MG
  • Catabasis Pharmaceuticals
  • Constellation
  • Dendright
  • Incuron
  • MedDay Pharmaceutical
  • MORE
Executive Summary

Overview

Introduction

Structure

Mechanism of Action

Inducers

Repressors

Clinical Significance

NF-kB Inhibitors

Pipeline Therapeutics (Active Products)

Pipeline Therapeutics (Inactive Products)

Comparative Analysis

Late Stage Products (Phase III)

Comparative Analysis

AMG0101: AnGes MG

Product Description

Research and Development

Product Development Activities

The list continues….

Mid Stage Products (Phase II)

Comparative Analysis

CPI-0610: CONSTELLATION

Product Description

Research and Development

Product Development Activities

The list continues….

Early Stage Products (Phase I)

Comparative Analysis

Pre-clinical Stage Products

Comparative Analysis

Therapeutic Assessment: Active Products

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Inactive Products (Dormant & Discontinued Products)

Comparative Analysis

Appendix
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AnGes MG
  • Catabasis Pharmaceuticals
  • Constellation
  • Dendright
  • Incuron
  • MedDay Pharmaceutical
  • Neurmedix
  • Realm Therapeutics
  • Reata Pharmaceuticals
  • Tracon Pharmaceuticals
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll